AYTU BIOPHARMA, INC
AYTU evidence brief
What we can confirm
- BioSniper Score:
- 8.5 / 10
- Market Cap:
- $21.4M
- Lead Asset:
- aciphex (Approved)
What it means
What to watch
Prepared research question
What matters most for AYTU—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · AYTU
AYTU BioPharma is a pharmaceutical company focused on commercializing prescription therapeutics for central nervous system disorders, centered on the recently launched antidepressant EXXUA and established ADHD and pediatric product portfolios.
Key risk: Commercial execution risk for EXXUA
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 7 pipeline candidates · 1 clinical trial · 6 catalysts · 3 FDA decisions for AYTU BIOPHARMA, INC.
AYTU BioPharma is a pharmaceutical company focused on commercializing prescription therapeutics for central nervous system disorders, centered on the recently launched antidepressant EXXUA and established ADHD and pediatric product portfolios.
- Focused on advancing innovative medicines for complex central nervous system diseases [sec_mda · as of 2026-09-22].
- Successfully launched EXXUA (gepirone hydrochloride) in fiscal 2026 as a novel first-in-class selective serotonin 5HT1a receptor agonist for major depressive disorder [sec_mda · as of 2026-09-22].
- Commercial portfolio includes ADHD products (Adzenys, Cotempla) and a pediatric product (Karbinal) [sec_mda · as of 2026-09-22].
- Cash & equivalents of $26.3M and shareholders' equity of $35.3M as of 2026-06-30 [sec].
- Indefinitely suspended active clinical development programs and divested its Consumer Health business to focus on commercial growth and positive operating cash flows [sec_mda · as of 2026-05-13].
What works
- EXXUA is the only antidepressant acting on serotonin receptors that does not carry a label warning about the risk of sexual dysfunction, a potential differentiator in the $22 billion U.S. MDD market [sec_mda · as of 2026-05-13].
- EXXUA has been extensively studied in over 5,000 patients and is approved by the FDA for the treatment of MDD in adults [sec_mda · as of 2026-05-13].
- The company has a focused commercial strategy with two established product portfolios (ADHD and Pediatric) providing ongoing revenue streams [sec_mda · as of 2026-09-22].
- Management has taken decisive steps to streamline operations by winding down unprofitable businesses and suspending early-stage development, concentrating resources on commercial execution [sec_mda · as of 2026-05-13].
What to weigh
- The company has suspended active development of its clinical pipeline, leaving future growth dependent on the commercial success of EXXUA and existing marketed products [sec_mda · as of 2026-05-13].
- EXXUA faces a competitive landscape with multiple competitors in Phase 2 and Phase 3 for similar indications, including SSRIs/SNRIs and other novel mechanisms [pipeline].
- The ADHD portfolio (Adzenys, Cotempla) competes against numerous other stimulant and non-stimulant ADHD treatments, some of which are in later-stage development [pipeline].
- The company's financial condition shows relatively modest cash reserves ($26.3M as of 2026-06-30) which may limit the ability to invest in large-scale commercial launches or R&D without achieving positive operating cash flows [sec].
From the filings
Quoted directly from source documents.
EXXUA is a novel first-in-class selective serotonin 5HT1a receptor agonist approved for MDD.
“EXXUA is a novel first-in-class selective serotonin 5HT1a receptor agonist and is approved by the FDA for the treatment of MDD in adults.”
SEC MD&A · May 13, 2026
EXXUA does not carry a label warning about sexual dysfunction.
“EXXUA is the only antidepressant acting on serotonin receptors that does not carry a label warning about the risk of sexual dysfunction.”
SEC MD&A · May 13, 2026
The company has suspended active development of clinical programs.
“we indefinitely suspended active development of our clinical development programs”
SEC MD&A · May 13, 2026
Catalyst timeline
- 2029-03-29 · Patent_Expiry · CARBINOXAMINE MALEATE — Patent expiry for NDA022556; may open market to generic competition for Karbinal.
- 2030-09-02 · Patent_Expiry · GEPIRONE HYDROCHLORIDE — Patent expiry for NDA021164; could allow generic versions of EXXUA.
- 2032-06-28 · Patent_Expiry · AMPHETAMINE — Patent expiry for NDA204326; may affect Adzenys XR-ODT.
- 2032-08-07 · Patent_Expiry · ZOLPIDEM TARTRATE — Patent expiry for NDA022196; potential generic competition for a product in the portfolio.
- 2033-05-29 · Patent_Expiry · SUVOREXANT — Patent expiry for NDA204569; may impact any related product.
- 2038-01-25 · Patent_Expiry · METHYLPHENIDATE — Patent expiry for NDA205489; could affect Cotempla XR-ODT.
Risks & what to watch (4)›
Key risks
- Commercial execution risk for EXXUA — EXXUA launch in fiscal 2026 is critical; failure to gain market share could strain cash reserves [sec_mda · as of 2026-09-22].
- No active pipeline beyond marketed products — Suspension of clinical development leaves no near-term new product catalysts, increasing reliance on existing portfolio [sec_mda · as of 2026-05-13].
- Competitive pressure in ADHD and MDD markets — Multiple competitors in Phase 2/3 for MDD and ADHD could erode market share for EXXUA, Adzenys, and Cotempla [pipeline].
- Limited financial runway — Cash of $26.3M may be insufficient to sustain prolonged commercial losses without achieving positive operating cash flows [sec].
What to watch
- Fiscal 2026 full year and fourth quarter operational and financial results reported on September 22, 2026 [catalyst].
- Revenue growth and market adoption of EXXUA in the MDD market [sec_mda · as of 2026-09-22].
- Achievement of positive operating cash flows from continuing operations [sec_mda · as of 2026-05-13].
- Any resumption of clinical development or new in-licensing/acquisition activity [sec_mda · as of 2026-09-22].
Sources: Catalysts · Pipeline · SEC MD&A · Generated October 13, 2026 · How we verify sources →
Run AYTU BIOPHARMA, INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available AYTU BIOPHARMA, INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 1.98
Lead: Approved
7 candidates
6 upcoming, next in ~897d
No insider transactions in the last 180 days
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
36
Total value held
$10.2M
| Holder | Shares | Value |
|---|---|---|
| nantahala capital management, llc | 1,086,812 | $3.0M |
| stonepine capital management, llc | 792,289 | $2.2M |
| awm investment company, inc. | 619,574 | $1.7M |
| diadema partners lp | 353,077 | $964K |
| vanguard capital management llc | 261,146 | $713K |
| two sigma investments, lp | 121,973 | $333K |
| renaissance technologies llc | 93,723 | $256K |
| persistent asset partners ltd | 92,897 | $254K |
| geode capital management, llc | 92,636 | $253K |
| vanguard fiduciary trust co | 47,048 | $128K |
Showing top 10 of 36 institutional holders of AYTU BIOPHARMA, INC. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 5.5%
- Days to cover
- 14.8
- Shares short
- 505,368
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
AYTU short interestGovernance
Frequently asked questions
What is the AI investment thesis for AYTU BIOPHARMA, INC?
AYTU BioPharma is a pharmaceutical company focused on commercializing prescription therapeutics for central nervous system disorders, centered on the recently launched antidepressant EXXUA and established ADHD and pediatric product portfolios.
What is AYTU BIOPHARMA, INC's lead drug candidate?
AYTU BIOPHARMA, INC's most advanced tracked candidate is aciphex (Approved).
What is AYTU BIOPHARMA, INC's next catalyst?
AYTU BIOPHARMA, INC's next tracked catalyst is a Patent_Expiry event — "Patent_Expiry: NDA022556" — expected March 29, 2029.
Who is the CEO of AYTU BIOPHARMA, INC?
Mr. Joshua R. Disbrow is the chief executive officer of AYTU BIOPHARMA, INC (AYTU).
Where is AYTU BIOPHARMA, INC headquartered?
AYTU BIOPHARMA, INC (AYTU) is headquartered in Denver, CO, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.